Vivos Therapeutics Secures $4.5M Debt-to-Equity Deal to Avoid Nasdaq Delisting

Event summary

  • Vivos Therapeutics has agreed to exchange up to $4.5M in debt with Streeterville Capital for preferred and common stock.
  • The deal includes a 90-day suspension of debt repayment calls and a 60-day moratorium on sales of company securities.
  • The transaction is contingent on completing one or more qualifying equity financings.
  • Vivos acquired The Sleep Center of Nevada in June 2025, transforming its business model and revenue potential.

The big picture

Vivos Therapeutics' debt-to-equity exchange with Streeterville Capital is a strategic move to avoid Nasdaq delisting and improve liquidity. The transaction follows the company's acquisition of The Sleep Center of Nevada, which marked a significant shift in its business model. The deal highlights the challenges faced by medical device companies in maintaining compliance with exchange listing standards while managing debt obligations.

What we're watching

Liquidity Dynamics
Whether the debt-to-equity exchange and contemplated equity raise will sufficiently improve Vivos' stockholders' equity to comply with Nasdaq's listing standards.
Execution Risk
The pace at which Vivos can secure additional financing to satisfy the conditions of the debt-to-equity exchange.
Strategic Integration
How the acquisition of The Sleep Center of Nevada will impact Vivos' revenue and earnings potential in the long term.